Creatine is best known as a workout supplement that helps muscles recover faster and perform harder. But a new systematic review published June 30, 2026, has examined whether its role in brain energy metabolism might also make it a useful addition to depression treatment, with mixed but potentially meaningful results.
The review, published in the journal Brain Medicine and announced on ScienceDaily on June 30, examined six published reports from five randomized controlled trials. Together, the trials enrolled 238 participants — 126 who received creatine and 112 who received placebo — across institutions in South Korea, the United States, Brazil, India, and Israel. Four trials focused on people with major depressive disorder; one studied people with bipolar disorder in a depressive episode.
The findings suggest that creatine, when used as an adjunct to existing antidepressant medications or psychotherapy, may produce faster and more robust symptom improvement for some patients. But researchers were clear: the evidence is preliminary, the trials were small, and current treatment recommendations have not changed.
Why This Matters
Depression affects approximately 21 million American adults annually, according to the National Institute of Mental Health. Despite decades of pharmacological research, a substantial fraction of patients — estimates range from 30% to 50% — do not achieve adequate response to first-line antidepressant treatment. Treatment-resistant depression remains one of the most significant unmet needs in psychiatry.
Creatine's relevance to brain function comes from a well-established biochemical role: it serves as a rapid energy buffer, donating a phosphate group to regenerate adenosine triphosphate (ATP) — the molecule cells use as fuel. The brain, which consumes approximately 20% of the body's energy despite representing only 2% of its weight, depends heavily on this energy-replenishment system.
Depression has been associated with abnormalities in brain energy metabolism in multiple research contexts. Reduced phosphocreatine levels in mood-relevant brain regions have been documented in some depressive patients. That biological finding is the rational basis for investigating whether creatine supplementation could address an energy deficit component of depression.
What We Know So Far
From the systematic review published in Brain Medicine (June 30, 2026) and related reporting by MedicalXpress and ZME Science:
- Trials reviewed : 5 RCTs (6 published reports), conducted in 5 countries
- Participants : 238 total (126 creatine; 112 placebo); average age 36; 74% female
- What trials tested : Creatine as an adjunct (added to) antidepressants or cognitive behavioral therapy, not as a standalone treatment
- Positive signals : Two trials focused on major depressive disorder showed potential benefit. One found that adding creatine to the antidepressant escitalopram improved symptoms. Another found that adding creatine to cognitive behavioral therapy produced a greater reduction in depressive symptoms than therapy plus placebo.
- Null finding : In one trial, creatine doses of 5g or 10g had no effect among patients who had already failed to respond to prior medication
- Gender pattern : The clearest effects appeared in women, which some researchers have linked to findings that women show lower baseline brain creatine levels in some studies
- Evidence quality : Two RCTs were rated low risk of bias; three had "some concerns" in quality assessment
What Doctors and Experts Say
"Based on the current evidence, there may be a signal for a faster and more robust response with adjunctive creatine," said Nicholas Fabiano, one of the study authors. "However, more research is needed."
Fabiano emphasized that the current research base has examined creatine only as an adjunctive treatment — added to antidepressants or therapy — not as a standalone treatment. Using creatine as a replacement for prescribed medication or psychotherapy is not what any of the reviewed trials tested or supported.
Independent psychiatrists reviewing the research have noted that the biological rationale for creatine in depression is more specific than for most dietary supplement interventions — the brain energy metabolism abnormalities observed in some depressed patients provide a mechanistic target, unlike supplements whose proposed benefits rest primarily on epidemiological associations.
What the Evidence Shows — and What It Does Not
This is a systematic review of small, heterogeneous trials — not a definitive clinical trial. The five trials differed substantially in design, dosing, population characteristics, and duration, which is why the researchers did not combine the data into a single pooled statistical analysis (meta-analysis). That methodological decision reflects intellectual honesty about the limitations of the available evidence.
MedicalDaily Evidence Check
- Review type : Systematic review of randomized controlled trials
- Published in : Brain Medicine (Open Access, June 30, 2026)
- Trials included : 5 RCTs, 238 participants total
- What it found : Signals of potential benefit when creatine is added to antidepressants or therapy in some patients, particularly women; null results in one treatment-resistant sample
- What it did not prove : That creatine works as a standalone antidepressant; that current treatment guidelines should change; that results apply to all depressed patients
- Key limitation : All trials were small; some had methodological concerns; the evidence base is insufficient to make clinical recommendations
- What readers should know : Creatine is not a treatment for depression at this stage; do not discontinue prescribed medications; discuss any supplement use with a prescribing clinician
Who May Eventually Benefit?
Based on current evidence signals, the patients for whom creatine adjunct therapy might eventually prove useful — if larger trials confirm benefits — are:
- Adults with major depressive disorder currently taking an SSRI or SNRI who have not achieved full remission
- Patients undergoing cognitive behavioral therapy whose symptom improvement has plateaued
- Vegetarians and vegans, who tend to have lower baseline creatine levels and may show greater response to supplementation
- Women, in whom lower brain creatine baseline levels have been reported in some neuroimaging research
Symptoms and Warning Signs to Watch For
Depression symptoms that warrant professional evaluation include:
- Persistent low mood lasting more than two weeks
- Loss of interest or pleasure in previously enjoyed activities
- Sleep disturbances (insomnia or sleeping excessively)
- Fatigue and loss of energy
- Feelings of worthlessness or excessive guilt
- Difficulty concentrating or making decisions
- Unexplained physical symptoms (pain, headaches)
- Thoughts of self-harm or suicide
If you or someone you know is experiencing thoughts of self-harm or suicide, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.
What You Can Do Now
- Do not stop taking prescribed antidepressants based on this research. The evidence is preliminary, and the trials tested creatine only as an add-on to medication — not as a replacement.
- If you are not achieving adequate symptom relief on current treatment , talk with your psychiatrist or prescriber about treatment augmentation options. Creatine may eventually be one option to discuss; lithium, atypical antipsychotics, and other evidence-based augmentation strategies already have a stronger evidence base.
- If you are curious about creatine supplementation , discuss it with your prescribing clinician before starting, as with any supplement used alongside medications.
- Vegetarians, vegans, and women who have not seen full symptom improvement on their current regimen may want to specifically ask their clinician whether creatine augmentation is worth exploring.
- Do not purchase creatine from sources making specific depression treatment claims. The research does not support marketing claims that creatine treats depression; it suggests a possible signal worth investigating in properly designed trials.
Cost and Access: What Patients Should Know
Creatine monohydrate is widely available as a dietary supplement, typically in powder form, at a cost of approximately $15 to $30 per month for typical doses (3–5 grams daily). However, because it has not been tested as a standalone antidepressant treatment and current clinical recommendations have not changed, insurance would not be expected to cover it for depression.
For patients who cannot afford or access current first-line antidepressant treatment, the SAMHSA National Helpline (1-800-662-4357) can provide referrals to local mental health services, including sliding-scale and no-cost options.
What Happens Next
The review authors called for larger, more rigorously designed randomized controlled trials to determine whether the signals identified in the five reviewed studies are reproducible and clinically meaningful. Trials with larger sample sizes, more consistent dosing protocols, and longer follow-up durations would substantially strengthen the evidence base.
The research community is also interested in whether neuroimaging tools — such as phosphorus MRS brain imaging that can directly measure brain phosphocreatine levels — could identify which depressed patients are most likely to benefit from creatine augmentation before treatment begins.
The Bottom Line
A systematic review of five randomized controlled trials published June 30, 2026, found preliminary signals suggesting creatine may help some depressed patients respond better when added to their existing antidepressant medication or therapy. The evidence is early, the trials were small, and current treatment guidelines have not changed. Creatine should not be used as a substitute for prescribed treatment. But the biological rationale is sound, the safety profile of creatine is well-established, and the signal — particularly in women and when used as an adjunct — is worth larger, properly designed clinical investigation. For patients who are not fully responding to current treatment, this research is a signal to watch, not a recommendation to act on yet.
